Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia

A Multicenter, Open Label Study Of Maraviroc, Zidovudine And Lamivudine Twice Daily For The Treatment Of Antiretroviral Naïve HIV-Infected Patients With R5 HIV-1 In Russia

One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and lamivudine) and maraviroc as their first line HIV therapy. The aim is to assess the efficacy and safety of this combination in a Russian population of patients.

Inclusion Criteria:

• Over 18 years of age.
• R5 HIV infection on screening tropism test.
• Viral load >1,000 copies/mL.
• Never previously treated with anti-HIV medicines.

Exclusion Criteria:

• Previously treated with anti-HIV medicines.
• Hepatitis B co-infection.